HUMAN OVERSIGHT REQUIREMENTS IN BIO-AI SYSTEMS: ETHICAL AND LEGAL GOVERNANCE

1. INTRODUCTION

Bio-AI systems refer to technologies combining artificial intelligence with biological, biomedical, genetic, pharmaceutical and healthcare applications. These systems may assist in disease diagnosis, genomic analysis, drug discovery, personalised medicine, biological research and clinical decision-making.

Although Bio-AI systems can improve scientific accuracy and healthcare efficiency, excessive reliance on automated decisions may create serious ethical and legal concerns. These include algorithmic discrimination, inaccurate medical recommendations, privacy violations, insufficient accountability and risks to patient safety.

Human oversight ensures that qualified professionals retain meaningful authority to examine, challenge, correct and, where necessary, override AI-generated decisions. It is therefore an essential requirement for responsible biotechnology governance.

2. MEANING AND SCOPE OF HUMAN OVERSIGHT

Human oversight means maintaining appropriate human supervision over the development, deployment and operation of AI systems used in biological and medical applications.

Its major components include:

Clinical supervision: Qualified healthcare professionals review AI-generated diagnoses and treatment recommendations.

Scientific supervision: Researchers independently evaluate AI-generated biological research conclusions.

Ethical supervision: Institutional ethics committees assess potential harm and ethical implications.

Regulatory supervision: Competent authorities monitor compliance with applicable legal requirements.

Data supervision: Responsible personnel ensure lawful collection, processing and protection of biological information.

Emergency intervention: Authorised professionals can suspend or override unsafe automated decisions.

3. FUNDAMENTAL ETHICAL PRINCIPLES

A. HUMAN AUTONOMY: AI systems must not eliminate patients' ability to make informed decisions concerning their medical treatment.

B. ACCOUNTABILITY: Healthcare providers, developers and institutions must retain clearly defined responsibilities for decisions involving AI systems.

C. TRANSPARENCY: Patients should receive appropriate information when AI substantially influences their diagnosis or treatment.

D. NON-MALEFICENCE: AI systems must undergo appropriate safety evaluation to minimise foreseeable harm.

E. NON-DISCRIMINATION: Bio-AI systems should be evaluated for biases involving genetic characteristics, gender, age and socioeconomic circumstances.

F. PROFESSIONAL INDEPENDENCE: Medical professionals must retain the authority to question algorithmic recommendations rather than accepting automated outputs unquestioningly.

4. LEGAL AND REGULATORY FRAMEWORK IN INDIA

1. CONSTITUTION OF INDIA

Article 21 protects life, personal liberty and privacy. Article 14 provides protection against arbitrary and discriminatory decisions. These constitutional principles are relevant to automated healthcare decisions affecting individual rights.

2. DIGITAL PERSONAL DATA PROTECTION ACT, 2023

The Act regulates digital personal data processing and establishes obligations concerning consent, transparency, security and accountability. Identifiable genetic and medical information may fall within its scope.

3. DIGITAL INFORMATION TECHNOLOGY AND MEDICAL REGULATION

The Information Technology Act, 2000 and applicable medical regulatory requirements may become relevant to digital healthcare systems, cybersecurity and professional responsibilities.

4. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

These Rules establish requirements concerning clinical investigations, participant protection and ethics committee oversight, including where AI-supported medical research is involved.

5. MEDICAL DEVICE REGULATIONS

The Medical Devices Rules, 2017 provide a regulatory framework for medical devices. AI-enabled software may fall within the medical-device framework depending on its intended purpose and regulatory classification.

6. ICMR ETHICAL GUIDELINES

The National Ethical Guidelines for Biomedical and Health Research Involving Human Participants provide standards for ethical review, informed consent, confidentiality and responsible biomedical research.

5. IMPORTANT CASE LAWS

The following judgments provide relevant legal principles. Most are analogous authorities because Indian courts have not yet established a comprehensive body of case law specifically addressing human oversight in Bio-AI systems.

1. Justice K.S. Puttaswamy v. Union of India (2017) — DIRECT CONSTITUTIONAL PRIVACY AUTHORITY

The Supreme Court recognised privacy as a fundamental right. The judgment is relevant to AI systems processing genetic information, medical histories and other sensitive personal information.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) — DIRECT MEDICAL-CONSENT AUTHORITY

The Supreme Court emphasised informed consent in medical treatment. AI-generated recommendations cannot replace the requirement to obtain appropriate patient consent for medical procedures.

3. Jacob Mathew v. State of Punjab (2005) — DIRECT MEDICAL-ACCOUNTABILITY AUTHORITY

The Supreme Court examined professional negligence and the standard of care expected from medical practitioners. Healthcare professionals must exercise appropriate professional judgment even when using AI-assisted diagnostic technologies.

4. Suchita Srivastava v. Chandigarh Administration (2009) — ANALOGOUS AUTONOMY AUTHORITY

The Supreme Court recognised reproductive autonomy as an important aspect of personal liberty under Article 21. The judgment supports the importance of individual decision-making in sensitive biomedical interventions.

5. Common Cause v. Union of India (2018) — ANALOGOUS MEDICAL-AUTONOMY AUTHORITY

The Supreme Court recognised patient dignity and autonomy in end-of-life medical decisions. Its principles support meaningful human involvement in decisions concerning life, treatment and medical welfare.

6. Shreya Singhal v. Union of India (2015) — ANALOGOUS TECHNOLOGY-GOVERNANCE AUTHORITY

The Supreme Court examined constitutional protections concerning online expression and restrictions on digital communication. Its broader reasoning concerning legal accountability and constitutional safeguards is relevant to technology governance.

7. Montgomery v. Lanarkshire Health Board (2015) — DIRECT COMPARATIVE MEDICAL-CONSENT AUTHORITY

The UK Supreme Court held that doctors must disclose material risks that a reasonable person in the patient's position would consider significant. This principle is relevant when AI-assisted medical decisions influence treatment choices.

6. ESSENTIAL HUMAN OVERSIGHT REQUIREMENTS

Bio-AI institutions should establish the following safeguards:

Require qualified human review of high-impact clinical recommendations.

Provide mechanisms for challenging and overriding AI-generated decisions.

Maintain records of significant human interventions and automated recommendations.

Conduct regular accuracy, reliability and bias assessments.

Establish independent clinical and ethical oversight.

Clearly allocate responsibility between developers, healthcare providers and institutions.

Protect patient confidentiality and genetic information.

Provide appropriate disclosure concerning AI involvement in healthcare.

Establish procedures for investigating algorithm-related medical errors.

Suspend systems where serious safety concerns arise.

7. INTERNATIONAL REGULATORY FRAMEWORK

The European Union AI Act, 2024 establishes a risk-based regulatory framework for artificial intelligence. Article 14 specifically addresses human oversight of high-risk AI systems, requiring appropriate capabilities for human operators to monitor system operation and intervene where necessary.

WHO's guidance on Ethics and Governance of Artificial Intelligence for Health also emphasises human autonomy, transparency, accountability, inclusiveness and safety.

8. CONCLUSION

Human oversight is fundamental to the ethical and legal governance of Bio-AI systems. Although artificial intelligence can improve biological research, clinical diagnosis and pharmaceutical development, it should not eliminate professional responsibility or individual autonomy.

The principles established in Puttaswamy, Samira Kohli, Jacob Mathew and Common Cause provide important legal foundations for privacy, informed consent, medical accountability and patient autonomy.

Ultimately, responsible Bio-AI governance requires meaningful human intervention, independent evaluation, transparent decision-making, regulatory compliance and clearly defined institutional responsibility. Artificial intelligence should support qualified human judgment rather than replace accountability for decisions affecting human health, biological integrity and fundamental rights.